Actualización general de inmunoterapia en cáncer
Cancer is one of the leading causes of death worldwide. The success rate of conventional anticancer therapeutic approaches such as chemotherapy is limited by the non-specific toxicity and low specificity towards specific tumors, which are highly dependent on the mutational burden present on each pat...
Guardado en:
Autores principales: | Reyes,Sebastián J., González,Konstanza B., Rodríguez,Constanza, Navarrete-Muñoz,Camila, Salazar,Andrea P., Villagra,Alejandro, Caglevic,Christian, Hepp,Matías I. |
---|---|
Lenguaje: | Spanish / Castilian |
Publicado: |
Sociedad Médica de Santiago
2020
|
Materias: | |
Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000700970 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Avances en inmunoterapia celular contra el melanoma maligno
por: López,Mercedes, et al.
Publicado: (2004) -
Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
por: Marije J. Voskamp, et al.
Publicado: (2021) -
Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
por: A. V. Chetveryakov, et al.
Publicado: (2021) -
Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer
por: Huiqiu ZHANG, et al.
Publicado: (2021) -
Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
por: Nuttapong Ngamphaiboon, et al.
Publicado: (2021)